Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1983-7-8
|
pubmed:abstractText |
The efficacy of oral contraceptives (OC) in the treatment of primary dysmenorrhea in controlled studies varies from 50 to 80%. The addition of a prostaglandin synthetase inhibitor, naproxen, was found to afford pain relief to a further 70% of women with OC-resistant dysmenorrhea in a double-blind cross-over study comprising 39 patients. This effect was shown to be statistically significant at p = 0.0005. Our recommendation is that low-dose OCs should be the first choice as contraceptive agents for women with dysmenorrhea and that a prostaglandin synthetase inhibitor should be given when OCs are ineffective.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0300-8835
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
113
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
87-9
|
pubmed:dateRevised |
2008-2-21
|
pubmed:meshHeading |
pubmed-meshheading:6407271-Adolescent,
pubmed-meshheading:6407271-Adult,
pubmed-meshheading:6407271-Clinical Trials as Topic,
pubmed-meshheading:6407271-Contraceptives, Oral,
pubmed-meshheading:6407271-Cyclooxygenase Inhibitors,
pubmed-meshheading:6407271-Double-Blind Method,
pubmed-meshheading:6407271-Dysmenorrhea,
pubmed-meshheading:6407271-Female,
pubmed-meshheading:6407271-Humans,
pubmed-meshheading:6407271-Naproxen
|
pubmed:year |
1983
|
pubmed:articleTitle |
Naproxen in the treatment of OC-resistant primary dysmenorrhea. A double-blind cross-over study.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|